Related references
Note: Only part of the references are listed.Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency
Andrew S. Levey et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2020)
Redefining Blood Pressure Assessment - The Role of the Ambulatory Blood Pressure Monitoring Study for Drug Safety
Christine Garnett et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020
DIABETES CARE (2020)
Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Boris Bikbov et al.
LANCET (2020)
The global burden of chronic kidney disease
Paul Cockwell et al.
LANCET (2020)
Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability
Hans Ericsson et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2020)
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
Guntram Schernthaner et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial
Megumi Oshima et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
Novel insights into the disease transcriptome of human diabetic glomeruli and tubulointerstitium
Anna Levin et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
David C Wheeler et al.
Lancet Diabetes & Endocrinology (2020)
Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction
Eva Prescott et al.
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS (2020)
Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease
Daniel Pettersen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials
Lesley A. Inker et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial
Carol Pollock et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
Brendan L. Neuen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Adoption of New Glucose-Lowering Medications in the US-The Case of SGLT2 Inhibitors: Nationwide Cohort Study
Rozalina G. McCoy et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
Michael S. Kelly et al.
POSTGRADUATE MEDICINE (2019)
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
Hiddoj L. Heerspink et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Inflammation in Diabetic Kidney Disease
Rosa E. Perez-Morales et al.
NEPHRON (2019)
Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease
Radica Z. Alicic et al.
ADVANCES IN CHRONIC KIDNEY DISEASE (2018)
Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5-Lipoxygenase Activating Protein Inhibitor
Hans Ericsson et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2018)
Role of the Immune System in Diabetic Kidney Disease
Fionnuala B. Hickey et al.
CURRENT DIABETES REPORTS (2018)
Assessment of Pressor Effects of DrugsA New US FDA Draft Guidance for Industry
J. Rick Turner
THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2018)
Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM( Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial
Frank Ruschitzka et al.
EUROPEAN HEART JOURNAL (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Targeting inflammation in diabetic kidney disease: early clinical trials
Maria Vanessa Perez-Gomez et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010
Katherine T. Mills et al.
KIDNEY INTERNATIONAL (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Add-on therapy with montelukast in the treatment of Henoch-Schonlein purpura
Sheng-Hua Wu et al.
PEDIATRICS INTERNATIONAL (2014)
Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C
Lesley A. Inker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A New Equation to Estimate Glomerular Filtration Rate
Andrew S. Levey et al.
ANNALS OF INTERNAL MEDICINE (2009)
Avosentan Reduces Albumin Excretion in Diabetics with Macroalbuminuria
Rene R. Wenzel et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Estimating GFR using serum cystatin C alone and in combination with serum creatinine: A pooled analysis of 3,418 individuals with CKD
Lesley A. Stevens et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2008)
Effect of a multifactorial intervention on mortality in type 2 diabetes
Peter Gaede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Mechanisms of disease: Leukotrienes
Marc Peters-Golden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Roles of lipid mediators in kidney injury
Chuan-Ming Hao et al.
SEMINARS IN NEPHROLOGY (2007)
Progression to overt nephropathy in type 2 diabetes - The Casale Monferrato study
G Bruno et al.
DIABETES CARE (2003)
Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects:: The Insulin Resistance Atherosclerosis Study
A Festa et al.
KIDNEY INTERNATIONAL (2000)
Share Paper
